[HTML][HTML] PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
…, V Cavalieri, KH Lin, NR Javidi-Sharifi, E Toska… - Molecular cancer, 2023 - Springer
The PI3K/AKT/mTOR (PAM) signaling pathway is a highly conserved signal transduction
network in eukaryotic cells that promotes cell survival, cell growth, and cell cycle progression. …
network in eukaryotic cells that promotes cell survival, cell growth, and cell cycle progression. …
The present and future of PI3K inhibitors for cancer therapy
Phosphoinositide 3-kinase (PI3K) signaling regulates cellular proliferation, survival and
metabolism, and its aberrant activation is one of the most frequent oncogenic events across …
metabolism, and its aberrant activation is one of the most frequent oncogenic events across …
[HTML][HTML] Overview of the relevance of PI3K pathway in HR-positive breast cancer
One of the hallmarks of hormone receptor (HR)-positive breast cancer is its dependence on
the phosphatidylinositol-3-kinase (PI3K) pathway. Here, we review the epidemiologic, …
the phosphatidylinositol-3-kinase (PI3K) pathway. Here, we review the epidemiologic, …
PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer
Activating mutations of PIK3CA are the most frequent genomic alterations in estrogen
receptor (ER)–positive breast tumors, and selective phosphatidylinositol 3-kinase α (PI3Kα) …
receptor (ER)–positive breast tumors, and selective phosphatidylinositol 3-kinase α (PI3Kα) …
Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors
Activating mutations in PIK3CA are frequent in human breast cancer, and phosphoinositide
3-kinase alpha (PI3Kα) inhibitors have been approved for therapy. To characterize …
3-kinase alpha (PI3Kα) inhibitors have been approved for therapy. To characterize …
PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D
… Toska et al. found that PI3K inhibition activates a specific epigenetic regulator, the histone
methyltransferase KMT2D. The protein modifications catalyzed by KMT2D create a more open …
methyltransferase KMT2D. The protein modifications catalyzed by KMT2D create a more open …
[PDF][PDF] PDK1-SGK1 signaling sustains AKT-independent mTORC1 activation and confers resistance to PI3Kα inhibition
PIK3CA, which encodes the p110α subunit of PI3K, is frequently mutated and oncogenic in
breast cancer. PI3Kα inhibitors are in clinical development and despite promising early …
breast cancer. PI3Kα inhibitors are in clinical development and despite promising early …
Cell-autonomous Cxcl1 sustains tolerogenic circuitries and stromal inflammation via neutrophil-derived TNF in pancreatic cancer
By decoding connections between high-risk tumor genotypes, cell-autonomous inflammatory
programs, and myeloid-enriched/T cell–excluded contexts, we identify a novel role for …
programs, and myeloid-enriched/T cell–excluded contexts, we identify a novel role for …
Resistance to TRK inhibition mediated by convergent MAPK pathway activation
… e,f, Western blot for MAPK effectors and cell proliferation curves of LMNA–NTRK1 (e) and
LMNA–NTRK1, NTRK1 G595R (f) CRC cell lines with ectopic expression of KRAS G12A and …
LMNA–NTRK1, NTRK1 G595R (f) CRC cell lines with ectopic expression of KRAS G12A and …
ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer
Mutations in ARID1A, a subunit of the SWI/SNF chromatin remodeling complex, are the most
common alterations of the SWI/SNF complex in estrogen-receptor-positive (ER + ) breast …
common alterations of the SWI/SNF complex in estrogen-receptor-positive (ER + ) breast …